Cystic Fibrosis - Pulmozyme Prior Authorization Policy
Cigna prior authorization policy for Pulmozyme (dornase alfa inhalation solution) specifying coverage for cystic fibrosis, required prescriber specialty, duration of approval, and noncovered/not medically necessary uses.
Annual revisions noted with 'No criteria changes' for prior reviews; most recent review date 05/07/2025.
Coverage Summary & Criteria
Applicable Codes
| No codes listed |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.